Preoperative combined modality therapy for clinically resectable UT3 rectal adenocarcinoma

被引:122
作者
Grann, A
Feng, C
Wong, D
Saltz, L
Paty, PP
Guillem, JG
Cohen, AM
Minsky, BD
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Colorectal Serv, Dept Surg, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, New York, NY 10021 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2001年 / 49卷 / 04期
关键词
rectal cancer; oral chemotherapy; combined modality therapy; adjuvant therapy;
D O I
10.1016/S0360-3016(00)01529-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the acute toxicity, outcome, and sphincter preservation rates in patients with clinically resectable uT3 adenocarcinoma of the rectum treated with preoperative combined modality therapy. Methods and Materials: A total of 72 patients were treated from 12/90-7/98 with preoperative 50.4 Gy plus 2 cycles of concurrent 5-fluorouracil (5-FU) and leucovorin (LV) bolus daily x 5 followed by sharp or total mesorectal excision and 4 cycles of postoperative 5-FU and LV, Results: Individual Grade 3+ toxicities during preoperative therapy included diarrhea, 11%; bowel movements, 9%; leukopenia, 18%; tenesmus, 1%; and thrombocytopenia, 1%. Total Grade 3+ toxicity was 28%. The pathologic complete response (CR) rate was 13%, and an additional 9% had a clinical CR for a total CR rate of 22%. Of the 35 patients who were judged clinically by their operating surgeon to require an abdominoperineal resection (APR) and were therefore treated with the goal of sphincter preservation, 89% were able to undergo sphincter-preserving surgery. Of the 21 patients eligible for analysis, 81% had good to excellent sphincter function. The 3-year actuarial patterns of failure were 2% local, 8% abdominal, and 13% distant, The 3-year actuarial survival was 95%. Conclusions: Our data confirm our preliminary reports of encouraging rates of acute toxicity, local control, survival, sphincter preservation and function with preoperative combined modality therapy, It is an alternative approach for the treatment of uT3 clinically resectable rectal cancer. (C) 2001 Elsevier Science Inc.
引用
收藏
页码:987 / 995
页数:9
相关论文
共 57 条
[1]   Pathologic complete response predicts long-term survival following preoperative radiation therapy for rectal cancer [J].
Ahmad, NR ;
Nagle, DA ;
Topham, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (02) :284-284
[2]   High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer [J].
Alektiar, KM ;
Zelefsky, MJ ;
Paty, PB ;
Guillem, J ;
Saltz, LB ;
Cohen, AM ;
Minsky, BD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (01) :219-226
[3]  
ANNE P, 2000, P ASCO, V19, pA250
[4]   Preoperative radiotherapy (RT) for rectal cancer: Predictive factors of tumor downstaging and residual tumor cell density (RTCD): Prognostic implications [J].
Berger, C ;
deMuret, A ;
Garaud, P ;
Chapet, S ;
Bourlier, P ;
ReynaudBougnoux, A ;
Dorval, E ;
deCalan, L ;
Huten, N ;
leFloch, O ;
Calais, G .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (03) :619-627
[5]   Preoperative radiochemotherapy in rectal cancer: Long-term results of a phase II trial [J].
Bosset, JF ;
Magnin, V ;
Maingon, P ;
Mantion, G ;
Pelissier, EP ;
Mercier, M ;
Chaillard, G ;
Horiot, JC .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (02) :323-327
[6]  
BOTWOOD N, 1998, P ASCO, V17, pA277
[7]  
Bozzetti F, 1999, CANCER, V86, P398, DOI 10.1002/(SICI)1097-0142(19990801)86:3<398::AID-CNCR6>3.0.CO
[8]  
2-0
[9]  
Brown T., 1999, International Journal of Radiation Oncology Biology Physics, V45, P339, DOI 10.1016/S0360-3016(99)90392-9
[10]  
CARRARO S, 2000, P ASCO, V19, pA291